Home/Filings/4/0000899243-18-028098
4//SEC Filing

Andera Partners 4

Accession 0000899243-18-028098

CIK 0001603756other

Filed

Nov 1, 8:00 PM ET

Accepted

Nov 2, 7:40 PM ET

Size

24.9 KB

Accession

0000899243-18-028098

Insider Transaction Report

Form 4
Period: 2018-11-02
Transactions
  • Conversion

    Common Stock

    2018-11-02+799,228799,228 total(indirect: See footnote)
  • Conversion

    Common Stock

    2018-11-02+654,2372,690,795 total(indirect: See footnote)
  • Conversion

    Series B-1 Preferred Stock

    2018-11-02671,7330 total(indirect: See footnote)
    Common Stock (806,080 underlying)
  • Conversion

    Series C Preferred Stock

    2018-11-02545,1970 total(indirect: See footnote)
    Common Stock (654,237 underlying)
  • Conversion

    Common Stock

    2018-11-02+806,0801,605,308 total(indirect: See footnote)
  • Conversion

    Common Stock

    2018-11-02+431,2502,036,558 total(indirect: See footnote)
  • Purchase

    Common Stock

    2018-11-02$15.00/sh+866,666$12,999,9903,557,461 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2018-11-02345,0000 total(indirect: See footnote)
    Common Stock (799,228 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2018-11-02359,3750 total(indirect: See footnote)
    Common Stock (431,250 underlying)
Transactions
  • Conversion

    Common Stock

    2018-11-02+431,2502,036,558 total(indirect: See footnote)
  • Purchase

    Common Stock

    2018-11-02$15.00/sh+866,666$12,999,9903,557,461 total(indirect: See footnote)
  • Conversion

    Series B-1 Preferred Stock

    2018-11-02671,7330 total(indirect: See footnote)
    Common Stock (806,080 underlying)
  • Conversion

    Series C Preferred Stock

    2018-11-02545,1970 total(indirect: See footnote)
    Common Stock (654,237 underlying)
  • Conversion

    Common Stock

    2018-11-02+799,228799,228 total(indirect: See footnote)
  • Conversion

    Common Stock

    2018-11-02+806,0801,605,308 total(indirect: See footnote)
  • Conversion

    Common Stock

    2018-11-02+654,2372,690,795 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2018-11-02345,0000 total(indirect: See footnote)
    Common Stock (799,228 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2018-11-02359,3750 total(indirect: See footnote)
    Common Stock (431,250 underlying)
Footnotes (6)
  • [F1]Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.
  • [F2]Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series A preferred stock automatically converted into 2.31660 shares of the Issuer's common stock. The A preferred stock had no expiration date.
  • [F3]This report is filed jointly by Andera Partners ("Andera") and BioDiscovery 4 FCPR ("BioDiscovery"). 2,824,128 shares are held of record by BioDiscovery and 733,333 shares are held of record by BioDiscovery 5 ("BioDiscovery 5"). Andera is the manager of BioDiscovery and BioDiscovery 5 and may be deemed to have sole voting and dispositive power over the shares held by BioDiscovery and BioDiscovery 5.
  • [F4]Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-1 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-1 preferred stock had no expiration date.
  • [F5]Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-2 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-2 preferred stock had no expiration date.
  • [F6]Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The C preferred stock had no expiration date.

Issuer

Axonics Modulation Technologies, Inc.

CIK 0001603756

Entity typeother
IncorporatedFrance

Related Parties

1
  • filerCIK 0001757283

Filing Metadata

Form type
4
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 7:40 PM ET
Size
24.9 KB